Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Coronavirus Update: After Rumors Of Shortcut To Market, AZ Pledges To ‘Follow Science’ In Vaccine Trials

Plus: Moderna Confirms Japan Vaccine Supply Discussions

Executive Summary

The company reiterates core values to 'follow the science' and 'put patients first' after talk of an emergency use authorization without completing Phase III trials.

You may also be interested in...



Gottlieb: Staged Access To Coronavirus Vaccine Possible Through EUA

Former FDA Commissioner says agency could grant an EUA for a vaccine, but require it meet the standard for full approval, and then roll it out gradually with postmarket data collection.

Pfizer CEO: Vaccine Could Be Ready In October But Won't Be Hurried By Political Pressure

Bourla reassures on scientific integrity amid fears of a politically motivated Emergency Use Authorization.

Novavax Willing To Submit COVID-19 Vaccine Before Phase III Completed

US FDA Commissioner Hahn’s controversial statement about approval before the end of Phase III has at least one taker, which may concern public health observers.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID1131516

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel